Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells (Q47691851)

4 February 2018

title

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells (English)

1 reference

4 February 2018

author name string

Thorsten Gantke

1

1 reference

4 February 2018

Michael Weichel

2

1 reference

4 February 2018

Carmen Herbrecht

3

1 reference

4 February 2018

Uwe Reusch

4

1 reference

4 February 2018

Kristina Ellwanger

5

1 reference

4 February 2018

Ivica Fucek

6

1 reference

4 February 2018

Markus Eser

7

1 reference

4 February 2018

Thomas Müller

8

1 reference

4 February 2018

Remko Griep

9

1 reference

4 February 2018

Vera Molkenthin

10

1 reference

4 February 2018

Eugene A Zhukovsky

11

1 reference

4 February 2018

Martin Treder

12

1 reference

4 February 2018

publication date

17 August 2017

1 reference

4 February 2018

Protein Engineering Design and Selection

published in

1 reference

4 February 2018

volume

30

1 reference

4 February 2018

issue

9

1 reference

4 February 2018

page(s)

673-684

1 reference

4 February 2018

B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies

cites work

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A mathematical model for the rational design of chimeric ligands in selective drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Bispecific T-cell engagers for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Visualization of proteins in acrylamide gels using ultraviolet illumination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Dual targeting strategies with bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Affinity and kinetic analysis of Fcgamma receptor IIIa (CD16a) binding to IgG ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Catumaxomab: clinical development and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Natural killer cell cytotoxicity: how do they pull the trigger?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Soluble monomeric IgG1 Fc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

Model and Simulation of Multivalent Binding to Fixed Ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZX043

21 January 2018

Identifiers

DOI

10.1093/PROTEIN/GZX043

1 reference

4 February 2018

1 reference

4 February 2018